ADEF
RPRX icon

ABS Direct Equity Fund’s Royalty Pharma RPRX Stock Holding History

ABS Direct Equity Fund’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,600
Closed -$181K – 141
2026
Q1 		$181K Buy
+3,600
New +$158K 0.14% 84

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABS Direct Equity Fund's RPRX Position: Q2 2026 in Review

ABS Direct Equity Fund sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 3,600 shares — an estimated $181K sold.

ABS Direct Equity Fund first reported a position in RPRX in Q1 2026 and held it in 1 quarter. The position peaked at $181K in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • ABS Direct Equity Fund reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • ABS Direct Equity Fund sold 3,600 Royalty Pharma shares in Q2 2026, an estimated $181K.
  • ABS Direct Equity Fund first reported a position in Royalty Pharma in Q1 2026 and held it in 1 quarter.
  • ABS Direct Equity Fund's Royalty Pharma position peaked at $181K in Q1 2026.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.